VG201

News alerts, weekly reports and conference planners

Company:

ViroGin Biotech

Drug class:

IL-15R stimulant, IL-12 stimulant, IL-15 stimulant

Related drugs:

‹

›

7ms

The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors (ESMO Asia 2023)

Nanostring analysis of paired biopsies from the PR pts demonstrated upregulation of integrin signaling pathway, antigen-presenting MHC (HLA-DQA1 and HLA-DRB1) and chemokine receptor (CMKLR1) genes, and activation of CD8+ T cells. Conclusions Monotherapy with VG2025 demonstrated activity with a well-tolerant safety profile in pts with advanced solid tumors that progressed after standard of care therapy.

7 months ago

Clinical • P1 data • Oncolytic virus • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL15 (Interleukin 15)

VG201

1year

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors. (ASCO 2023)

Monotherapy activity was observed with an acceptable safety profile in heavily pretreated pts with advanced solid tumors. Clinical trial information: NCT05266612.

1 year ago

Clinical • P1 data • Oncolytic virus • Metastases

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CEACAM5 (CEA Cell Adhesion Molecule 5) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL15 (Interleukin 15)

VG201